Evaluation of Platelet Rich Fibrin / Biphasic Calcium Phosphate Effect Versus Autogenous Bone Graft on Reconstruction of Alveolar Cleft

NCT ID: NCT03302429

Last Updated: 2024-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-19

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

P- Maxillary alveolar cleft defects I- Platelet-rich fibrin (PRF) combined with biphasic calcium phosphate (BCP) C- Autogenous bone graft O- Outcome measure : bone height, bone volume, hospital stay, operation duration T- 6 months S- Randomized controlled clinical trial this study aimed to answer a clinical question whether the use of Platelet-rich Fibrin (PRF) combined with Biphasic Calcium Phosphate (BCP), can be an alternative to autogenous bone graft in reconstruction of alveolar cleft defect in maxillary arch.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

this study aimed to answer a clinical question whether the use of Platelet-rich Fibrin (PRF) combined with Biphasic Calcium Phosphate (BCP), can be an alternative to autogenous bone graft in reconstruction of alveolar cleft defect in maxillary arch

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alveolar Ridge Abnormality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Eighteen patients will be divided into two equal groups. Each group comprises nine patients.

Group A: Platelet-rich Fibrin combined with Biphasic Calcium Phosphate.(interventional group) Group B: autogenous bone graft (controlled group)
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRF/ BCP

Biphasic calcium phosphate (BCP)"bioceramic bone substitute combined with platelet rich fibrin PRF

Group Type EXPERIMENTAL

PRF/ BCP

Intervention Type OTHER

Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)

autogenous bone graft

Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft

Group Type ACTIVE_COMPARATOR

Autogenous bone graft

Intervention Type OTHER

Bone obtained from the same individual who receiving the graft

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRF/ BCP

Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)

Intervention Type OTHER

Autogenous bone graft

Bone obtained from the same individual who receiving the graft

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Easy-graft/BCP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients suffering from maxillary alveolar cleft
* Patients' age 8 years and older

Exclusion Criteria

* Syndromic cases will be excluded
* Patients suffering from platelets disorders.
Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hebatallah G Samra El-Shamy

resarcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Dentistry, Cairo University

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEBD-CU-2017-09-31

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.